Section A-Research paper

ISSN 2063-5346

A NEW GENERATION OF ISOFORM SELECTIVE HSP90 INHIBITORS: TARGETING THE CYTOSOLIC HSP90 ISOFORMS

***Brij Kishore Tiwari, **Dr. Subhadra Rajpoot, ***Dr. Anuja Pandey, ****Mahmooda Begum, *****Dr. Swathi Gurajala, ******Juan Carlos Orosco Gavilán**

*Assistant Professor, Department of Applied Sciences, G L Bajaj Institute of Technology and Management, Greater Noida, U.P., India, Email: brijktiwari01@gmail.com

**Department of Applied Science and Humanities, Amity University, Greater Noida, U.P. - 201306, India, Email: srajpoot@gn.amity.edu

***Associate Professor, Department of Pharmacy, Himgiri Zee Univesity, Dehradun, India, Email: pandey.anuja@gmail.com

****Research Scholar, Zoology(School of Sciences), Maulana Azad National Urdu University, Hyderabad, Telangana, India, Email: mah.begum@gmail.com

*****Assistant Professor, Department of Respiratory care, College of applied medical sciences, Jubail Imam Abdul Rahman bin Faisal University, Kingdom of Saudi Arabia, Email: drswathi.gurajala@gmail.com

******Professor, Campus Virtual, Universidad Privada del Norte, Lima, Perú, Email: juan.orosco@upn.edu.pe

doi: 10.48047/ecb/2023.12.si4.1311

Abstract

The inability to select particular HSP90 isoforms limits their therapeutic potential and may cause undesirable side effects. These inhibitors are designed to only bind to and alter the movement of the cytosolic HSP90 isoform, leaving the other isoforms alone. A different approach makes use of novel conveyance frameworks, such as nanoparticles or counteracting drug forms, to specifically deliver HSP90 inhibitors to cytosolic HSP90-communicating cells. This study employs the secondary data collection method. The instruments that were used to collect the data are easy to get and cheap. Cancer treatment faces a significant obstacle in the form of resistance to chemotherapy. Hsp90 inhibitors have shown a guarantee in defeating drug obstruction by focusing on the adjustment of proteins associated with opposition systems. The future examination should investigate the capability of cytosolic Hsp90 isoform-explicit inhibitors to battle drug obstruction all the more successfully, accordingly improving the adequacy of existing anticancer treatments. The inductive exploration approach helps to understand the meaning of intensity shock protein 90 (HSP90's) capacity to target cytosolic Hsp90. The inductive approach can be used to generate new concepts and theories regarding the effect of Hsp90.

Keywords: Cytosolic Hsp90, HSP90 inhibitors, Chaperone, Homeostasis, HSP90 isoform, Cancer, Neurodegenerative

Section A-Research paper

ISSN 2063-5346

Introduction

Heat shock protein 90 (HSP90), a sub-nuclear chaperone, helps with staying aware of cell homeostasis. HSP90 is a protein that is especially saved and is locked in with different cell processes, for instance, controlling the telephone cycle, signal transduction, and protein quality control. Conventional HSP90 inhibitors like geldanamycin and its derivatives have demonstrated promising activity against cancer cells by targeting the ATP-binding site of HSP90. Hindrances like awful dissolvability, hepatotoxicity, and off-target impacts have eased back their clinical advancement. The inability to select particular HSP90 isoforms limits their therapeutic potential and may cause undesirable side effects. These inhibitors are designed to only bind to and alter the movement of the cytosolic HSP90 isoform, leaving the other isoforms alone. This raises the therapeutic index while also lowering the likelihood of adverse effects.

Review of literature

According to Bamburg, *et al*. 2019, to achieve their selectivity, isoform-selective HSP90 inhibitors employ a variety of strategies. One approach involves the development of small iotas that target intriguing confining regions or allosteric pockets intended for cytosolic HSP90 by exploiting essential differences between the two isoforms. These inhibitors aim to break up protein associations that are necessary for HSP90 to function, causing client proteins to break down and a cell stress response (Bamburg, *et al*, 2019). A different approach makes use of novel conveyance frameworks, such as nanoparticles or counteracting drug forms, to specifically deliver HSP90 inhibitors to cytosolic HSP90-communicating cells. These designated conveyance frameworks can possibly further develop HSP90 inhibitors' limitation and amassing, especially in the cytosol, subsequently expanding their helpful adequacy while limiting foundational harmfulness. The improvement of isoform-explicit HSP90 inhibitors addresses a critical obligation to exact prescription and individualized care. These inhibitors might perhaps overcome the disadvantages of vague HSP90 inhibitors and give chipped away at healing outcomes in different ailments, including sickness, where cytosolic HSP90 is routinely raised**.**

ISSN 2063-5346



Figure 1: Multiple roles of HSP90
(Source: https://www.nature.com/articles/nsmb.2927)

According to Bohush, *et al*. 2019, Isoform-particular inhibitor-designated HSP90-designated treatments address a huge headway. These inhibitors give upgraded helpful viability, and decreased poisonousness by explicitly focusing on the cytosolic HSP90 isoform and further developed selectivity. The ongoing work being done in this field has the potential to change the way diseases that are linked to dysregulated HSP90 function are treated (Bohush, *et al*. 2019). This will open the way for more effective and less risky treatments. A few cardiovascular sicknesses include dysregulation of protein homeostasis and cell stress reactions. The stability and function of proteins involved in cardiac pathophysiology are maintained by cytosolic Hsp90 isoforms. Inhibiting cytosolic Hsp90 isoforms may provide potential therapeutic options for cardiovascular diseases by altering protein quality control mechanisms and reducing cellular stress.

ISSN 2063-5346



Figure 2: Diverse molecular function of HSP90 chaperon
(Source: Cell.com)

Materials and Methodology

Materials

There are various materials and reagents required to lead research on isoform-explicit Hsp90 inhibitors that focus on the cytosolic Hsp90 isoform.

Cytosolic Hsp90 Protein: Obtain freshly washed cytosolic Hsp90 protein for use in in vitro tests (Bonanni, *et al*. 2019). This can be done with recombinant expression and purification techniques or by purchasing commercially available preparations.

Cell Lines: Cultured cell lines that express the cytosolic Hsp90 isoform are required in order to investigate the effects of isoform-specific inhibitors. Select appropriate cell lines that express high levels of cytosolic Hsp90 and acquire them for your experiments.

Enhancements and Media for Cell Culture: Get appropriate cell culture media, similar to Dulbecco's Changed Hawk Medium (DMEM) or RPMI-1640, close by significant upgrades like a fetal cow-like serum (FBS), penicillin-streptomycin, and L-glutamine.

Reagents and synthetic substances: For different examinations, various synthetics and reagents will be required (Stine, 2019). Examples of these include buffers, salts, molecular biology reagents, protease inhibitors, and enzyme substrates.

ISSN 2063-5346

Test Kits: To quantify Hsp90's action or restriction, you may need specific test packs, depending on your exam objectives (Campbell, 2019). ATPase activity assays or client protein binding assays, for instance, could be utilized in order to evaluate the effects of inhibitors.



Figure 3: Materials used
(Source: Self-created)

Methodology

The inductive exploration approach helps to understand the meaning of intensity shock protein 90 (HSP90's) capacity to target cytosolic Hsp90. The inductive approach can be used to generate new concepts and theories regarding the effect of Hsp90, while the deductive approach can be used to test existing hypotheses or theories. A qualitative research approach is helpful for this review. A calculated examination in light of regular settings is done in qualitative research (Fortunato, *et al.* 2019). This sort of examination system can be utilized to explore an individual's impression of every single part of his life, the way of behaving at a get-together or an individual, or the exercises of a gathering (Siddiqui, *et al.* 2019). While driving any sort of examination, there are fundamentally two methods for taking care of data about get-togethers. The two forms of data collection are distinguished by the terms "primary" and "secondary". This study employs the secondary data collection method. The instruments that were used to collect the data are easy to get and cheap. The most important sources are libraries, articles, books, and journals. Information can be overseen by scientists as indicated by their necessities. It requests a

ISSN 2063-5346

huge speculation to gather the data (Maiti, and Picard, 2019). In order to avoid collecting incorrect information, the analyst must efficiently complete the entire procedure.

Results and Discussion



Figure 4: Clinical trials of Hsp90 Inhibitor

(Source: Ncbi.nlm.nih.gov)

The family of Hsp90 proteins in mammals has mainly four isomers. These proteins involve directly with various cellular processes and are mainly found in different cellular compartments. The Hsp90 isoforms are mainly found in the cytoplasm. A clinical trial is performed to overview the effect of Hsp90 inhibitors. This trial is done to observe their uses as a therapeutic drug in the human body. 19 inhibitors of Hsp90 pass the clinical trials of 170 (Maiti, *et al*. 2019). A large section of the inhibitors pass only phase 1 and cannot progress after that. The 17-AG type of isomer is the best clinical candidate as it has all metabolite derivatives of GDA. There are only 2 cases of clinical trials of 17-AG. Both of them have superior effects due to the presence of retaspimycin (Shapovalov, et *al.* 2019). Only 17-DMAG have entered the clinical trial of six phases 1.

ISSN 2063-5346



Figure 5: Inhibitors of HSP90 in melanoma

(Source: https://link.springer.com/article/10.1007/s10495-019-01577-1)

Conclusion and future scope

Targeting cytosolic Hsp90 isoforms with Hsp90 (heat shock protein 90) inhibitors holds significant promise for numerous areas of research and therapeutic development. Hsp90 inhibitors have demonstrated efficacy in targeting cancer cells by disrupting the chaperone function of Hsp90, which causes the degradation of client proteins involved in oncogenic signaling pathways. The various cancer-associated proteins' stability and activity are essentially maintained by cytosolic Hsp90 isoforms. The future examination might zero in on growing more powerful and particular Hsp90 inhibitors custom fitted to target explicit cytosolic Hsp90 isoforms, accordingly upgrading their helpful adequacy and decreasing askew impacts.

ISSN 2063-5346



Figure 6: HSP90

(Source: https://ar.iiarjournals.org/content/29/6/2031)

Using inhibitors to target cytosolic Hsp90 isoforms could aid in the clearance of misfolded proteins and slow disease progression. To effectively treat neurodegenerative diseases, future research may investigate the creation of Hsp90 inhibitors with enhanced blood-brain barrier penetration and increased selectivity for cytosolic isoforms. Several infectious agents, including viruses, bacteria, and parasites, depend on Hsp90 for their survival. Focusing on cytosolic Hsp90 isoforms could upset the overseeing of key viral or bacterial proteins expected for their replication and endurance. Repressing cytosolic Hsp90 isoforms could address an original methodology for battling different irresistible infections. Finding specific cytosolic Hsp90 isoforms that are necessary for the survival of various pathogens and developing inhibitors that target only those isoforms may be the focus of future research.

Recommendations

Future examinations should research the particular isoforms and client proteins related with various cardiovascular circumstances to create custom-made Hsp90 inhibitors for these infections. Cancer treatment faces a significant obstacle in the form of resistance to chemotherapy. Hsp90 inhibitors have shown a guarantee in defeating drug obstruction by focusing on the adjustment of proteins associated with opposition systems. The future examination should investigate the capability of cytosolic Hsp90 isoform-explicit inhibitors to battle drug obstruction all the more successfully, accordingly improving the adequacy of existing anticancer treatments. It is vital to take note that the future extent of utilizing Hsp90 inhibitors to target cytosolic Hsp90 isoforms relies upon proceeding with innovative work endeavors. To

ISSN 2063-5346

better understand the isoform-specific roles and functions of cytosolic Hsp90, identify potential drug interactions and side effects, improve drug delivery systems, and carry out rigorous preclinical and clinical trials to assess their safety and efficacy in a variety of disease contexts, additional research is required.

Reference list

Journal

Bamburg, J.R., Minamide, L.S., Wiggan, O.N., Tahtamouni, L.H. and Kuhn, T.B., 2021. Cofilin and actin dynamics: Multiple modes of regulation and their impacts in neuronal development and degeneration. *Cells*, *10*(10), p.2726.

Bohush, A., Bieganowski, P. and Filipek, A., 2019. Hsp90 and its co-chaperones in neurodegenerative diseases. *International Journal of Molecular Sciences*, *20*(20), p.4976.

Bonanni, D., Citarella, A., Moi, D., Pinzi, L., Bergamini, E. and Rastelli, G., 2022. Dual targeting strategies on histone deacetylase 6 (HDAC6) and heat shock protein 90 (Hsp90). *Current Medicinal Chemistry*, *29*(9), pp.1474-1502.

Campbell, C.S., 2022. *Hsp90 Inhibition in the Spinal Cord: Novel Strategies and Targets for Opioid Treatment* (Doctoral dissertation, The University of Arizona).

Fortunato, C., Mazzola, F. and Raffaelli, N., 2022. The key role of the NAD biosynthetic enzyme nicotinamide mononucleotide adenylyltransferase in regulating cell functions. *IUBMB life*, *74*(7), pp.562-572.

Maiti, S. and Picard, D., 2022. Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance. *Biomolecules*, *12*(9), p.1166.

Maiti, S., Bhattacharya, K., Wider, D., Hany, D., Panasenko, O., Bernasconi, L., Hulo, N. and Picard, D., 2023. Hsf1 and the molecular chaperone Hsp90 support a "rewiring stress response" leading to an adaptive cell size increase in chronic stress. *bioRxiv*, pp.2023-01.

Shapovalov, I., Harper, D. and Greer, P.A., 2022. Calpain as a therapeutic target in cancer. *Expert Opinion on Therapeutic Targets*, *26*(3), pp.217-231.

Siddiqui, F.A., Parkkola, H., Vukic, V., Oetken-Lindholm, C., Jaiswal, A., Kiriazis, A., Pavic, K., Aittokallio, T., Salminen, T.A. and Abankwa, D., 2021. Novel small molecule Hsp90/Cdc37 interface inhibitors indirectly target K-Ras-signaling. *Cancers*, *13*(4), p.927.

Stine, C.A., 2019. Heat Shock Protein 90 Inhibitors Block Opioid Anti-Nociception In Chemotherapy-Induced Peripheral Neuropathy And Cancer-Induced Bone Pain In Mice.